Life sciences company Thermo Fisher (NYSE: TMO) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 9.1% year on year to $12.14 billion. Its non-GAAP profit of $6.68 per share was 4.3% above analysts’ consensus estimates.

Is now the time to buy TMO? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Thermo Fisher delivered third quarter results that exceeded Wall Street’s expectations, with management crediting broad-based recovery across key end markets and improved customer activity in pharma and biotech. CEO Marc Casper pointed to high single-digit growth in pharma services and robust performance in electron microscopy, especially for semiconductor applications. The company also benefited from strategic investments made during the industry downturn, which are now supporting stronger market share and operational execution. Casper described the period as an “incredibly exciting time” for the company’s customers, citing renewed confidence and expanding pipelines in biotech and pharma.

Looking ahead, Thermo Fisher’s updated guidance is anchored by expectations of continued momentum in pharma services, expansion in clinical research, and the integration of AI across its portfolio. Management highlighted that investments in innovation and capacity are positioning the business to capture further share as end markets stabilize. CFO Jim Meyer indicated that while certain segments, such as bioscience reagents, remain muted, new launches and customer collaborations are expected to drive growth. Casper emphasized that AI is enabling both improved internal productivity and new value propositions for customers, saying, “the brighter the future is” as AI accelerates drug development and research workflows.

Key insights from management’s remarks

Management attributed quarterly outperformance to strong execution in pharma services and analytical instruments, ongoing investments in innovation, and improved demand across geographies.

• Pharma services acceleration: The pharma and biotech end markets saw high single-digit growth, with pharma services notably benefiting from increased customer activity and investments in capacity during the industry downturn. Management highlighted that confidence and funding in biotech are returning, supporting a positive outlook for the sector.

• Analytical instruments strength: The electron microscopy business delivered strong growth, largely driven by demand from the semiconductor industry. Management noted that Thermo Fisher’s market-leading technologies are critical to next-generation research and manufacturing, which is contributing to share gains in this segment.

• AI-driven product innovation: Thermo Fisher launched several AI-enabled products, including the Orbitrap Isora mass spectrometer and new electron microscopy software, which automate workflows and enhance research capabilities. These advancements are making sophisticated analyses more accessible and efficient for customers.

• Geographic expansion: Asia Pacific, and China in particular, delivered low double-digit growth, with management emphasizing improved market conditions and successful commercial execution in these regions. The opening of an AI-Automation Innovation Center in South Korea was cited as a key initiative to deepen customer collaboration and drive adoption of advanced workflows.

• Portfolio optimization and integration: The company completed the divestiture of its microbiology business and celebrated the one-year anniversary of its filtration and separation acquisition, both of which are shaping the business mix. The integration of the Clario acquisition is progressing smoothly, and management expects meaningful revenue synergies as these capabilities are incorporated into the broader offering.

Drivers of future performance

Thermo Fisher’s outlook is driven by continued recovery in life sciences demand, further AI integration, and investments in capacity and new product development.

• Pharma and biotech momentum: Management expects sustained growth in pharma services and clinical research, supported by rising demand for outsourced development and manufacturing. Growth in biotech is anticipated to broaden from clinical research and channel businesses into higher-margin reagent sales as pipelines and funding improve.

• AI-enabled differentiation: Investments in AI are expected to enhance customer productivity and enable new scientific workflows. Management believes AI will drive incremental demand for both instruments and services, fostering a virtuous cycle where improved returns on drug development fuel further industry investment.

• Potential headwinds and execution risks: While end market conditions have improved, management noted that certain areas, such as bioscience and genetic reagent sales, remain soft. The pace of normalization in these segments and successful integration of recent acquisitions, like Clario, will be key variables influencing results in the next year.

Catalysts in upcoming quarters

In the coming quarters, the StockStory team will be watching (1) the continued expansion of pharma and biotech activity into higher-value reagent and instrumentation sales, (2) the pace and impact of AI adoption both internally and in customer-facing products, and (3) ongoing integration and revenue synergy realization from recent acquisitions like Clario. Progress in normalizing life sciences reagent demand and the success of new product launches will also be important indicators.

Thermo Fisher currently trades at $697.65, up from $687.37 just before the earnings. Is the company at an inflection point that warrants a buy or sell? The answer lies in our full research report (it’s free).

Our favorite stocks right now

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.